Official Journal of the Italian Society of Orthopaedics and Traumatology
From: Nicotine consumption may lead to aseptic loosening in proximal mega-prosthetic femoral replacement
Patient | Gender | Age | DM | RA | Nicotine | Reason for replacement | Implant at hip prior to operation | Manufacturer |
---|---|---|---|---|---|---|---|---|
1 | M | 76.0 | – | – | NS | Metastasis urothel-carcinoma | – | Cremascoli |
2 | M | 66.8 | – | – | S (49 py) | Malignant histiocytoma | – | Cremascoli |
3 | F | 66.9 | – | – | NS | Metastasis mamma-carcinoma | – | Implantcast |
4 | F | 75.4 | – | – | NS | Metastasis mamma-carcinoma | – | LINK |
5 | F | 62.3 | Yes | – | NS | Metastasis mamma-carcinoma | – | Implantcast |
6 | M | 73.6 | – | – | NS | Plasmocytoma | Standard hip endoprosthesis | Implantcast |
7 | F | 66.9 | Yes | – | NS | Plasmocytoma | – | Implantcast |
8 | M | 73.3 | – | – | S (52 py) | Metastatic adenocarcinoma prostate | – | Implantcast |
9 | M | 37.6 | – | – | S (20 py) | Chondrosarcoma | – | Implantcast |
10 left leg | F | 60.0 | – | – | NS | Metastasis mamma-carcinoma | Intramedullary femur nail | Implantcast |
10 right leg | F | 59.8 | – | – | NS | Metastasis mamma-carcinoma | Intramedullary femur nail | Implantcast |
11 | M | 55.4 | – | – | S (36 py) | Fibrous dysplasia, pathological fracture | – | Implantcast |
12 | F | 56.6 | – | – | NS | Metastasis mamma-carcinoma | Intramedullary femur nail | Eska Implants |
13 | M | 56.2 | – | – | NS | Metastatic renal cell carcinoma | – | Eska implants |
14 | F | 77.5 | Yes | Yes | NS | Bone loss after osteosynthesis | Intramedullary femur nail | Eska implants |
15 | F | 66.4 | – | – | NS | Metastatic renal cell carcinoma | Metal plate | Eska implants |
16 | M | 52.9 | – | – | NS | Metastatic renal cell carcinoma | – | Eska implants |
17 | F | 75.7 | – | – | NS | Metastatic renal cell carcinoma | – | Eska implants |
18 | M | 81.7 | – | – | S (67 py) | Bone loss after removal of hip prosthesis | Standard hip endoprosthesis | Eska Implants |
19 | M | 59.7 | – | – | NS | Chondrosarcoma | Standard hip endoprosthesis | Implantcast |
20 | F | 74.0 | – | – | NS | Plasmocytoma | Intramedullary femur nail | Eska implants |
21 | F | 66.6 | – | – | NS | Metastasis mamma-carcinoma | Intramedullary femur nail | Eska implants |
22 | F | 72.8 | – | – | NS | Bone loss after removal of hip prosthesis | Standard hip and knee endoprosthesis | Eska implants |
23 | M | 70.4 | – | – | NS | Metastatic renal cell carcinoma | – | Orthodynamics |
24 | F | 57.6 | – | – | NS | Bone loss after osteosynthesis | Intramedullary femur nail | Orthodynamics |
25 | M | 77.1 | Yes | Yes | NS | Metastasis bronchial adenocarcinoma | – | Orthodynamics |
26 | F | 60.9 | – | – | NS | Metastasis mamma-carcinoma | – | Orthodynamics |
Patient | Duration of operation (min) | Intra-/postoperative complications | Time primary operation-first following operation | Reasons for all implant related following operations | Amount of following related operations | Time to removal of implant (months) | Situation after implant removal | Time from implantation yo death or alive |
---|---|---|---|---|---|---|---|---|
1 | 267 | –/Wound infection, lymphatic edema | 10.2 months | Superficial infection (enterococcus faecalis, staphylococcus epidermidis) | 1 | 0.9 years | ||
2 | –/Hematoma, dislocation <3 months after surgery | 1 day | Hematoma, dislocation | 2 | 1.0 years | |||
3 | 158 | –/– | 0.4 years | |||||
4 | 146 | –/– | 0.6 years | |||||
5 | 143 | –/– | 3.0 years | |||||
6 | 260 | –/Dislocation >3 months after surgery | 1.3 years | |||||
7 | 108 | –/– | 1.7 years | |||||
8 | 155 | –/– | 0.1 years | |||||
9 | 300 | –/Aseptic shaft loosening | 71.0 months | Aseptic shaft loosening | 1 | 71.0 | Re-implantated proximal cemented femoral replacement | Alive |
10 left leg | –/Dislocation >3 months after surgery | 3.3 years | ||||||
10 right leg | –/– | 3.5 years | ||||||
11 | 229 | –/Aseptic shaft loosening | 12.0 months | Aseptic shaft loosening | 1 | 12.0 | Re-implantated proximal cemented femoral replacement | Alive |
12 | 273 | –/Wound infection, urinary tract infection | 6.0 months | Superficial infection (staphylococcus epidermidis, corynebacterium species) | 4 | 0.8 years | ||
13 | 242 | –/Wound infection | 5.2 months | Superficial infection (staphylococcus aureus) | 1 | 0.5 years | ||
14 | 306 | –/Sigma diverticulitis | 0.7 years | |||||
15 | 201 | –/Wound healing deficiency without infection | 4.2 months | Wound healing deficiency without infection | 1 | 0.9 years | ||
16 | 269 | –/Dislocation <3 months after surgery | 2.4 months | Dislocation | 1 | 5.3 years | ||
17 | 219 | –/– | Alive | |||||
18 | 341 | Femoral vein lesion / aseptic shaft loosening | 45.5 months | Aseptic shaft loosening | 1 | 45.5 | Total femoral replacement | Alive |
19 | –/Gluteal insufficiency, local tumor recurrence | 82.9 months | Local tumor recurrence | 1 | 82.9 | Hip ex-articulation without implant | Alive | |
20 | 240 | –/Dislocation >3 months after surgery, recurrent | 43.3 months | Dislocation | 1 | Alive | ||
21 | 244 | –/Wound infection, hematoma, urinary tract infection | 0.4 months | Superficial infection (staphylococcus haemolyticus), hematoma | 2 | 0.7 years | ||
22 | 295 | –/Wound infection | 12.5 months | Deep infection/septic loosening (MRSA, MRSE, staphylococcus capitis, campylobacter fetus) | 5 | 13.9 | Girdlestone situation with attendant femoral amputation | Alive |
23 | 240 | –/Dislocation >3 months after surgery | Alive | |||||
24 | 220 | –/– | Alive | |||||
25 | 183 | –/Dislocation >3 months after surgery | 0.4 years | |||||
26 | 224 | –/– | Alive |